Massachusetts Financial Services Co. MA Acquires Shares of 14,419 Pacira BioSciences, Inc. (NASDAQ:PCRX)

Massachusetts Financial Services Co. MA bought a new position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 14,419 shares of the company’s stock, valued at approximately $217,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. grew its position in Pacira BioSciences by 0.3% during the first quarter. Vanguard Group Inc. now owns 5,113,384 shares of the company’s stock worth $149,413,000 after buying an additional 14,960 shares in the last quarter. CANADA LIFE ASSURANCE Co grew its holdings in shares of Pacira BioSciences by 6.7% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 39,229 shares of the company’s stock worth $1,145,000 after purchasing an additional 2,455 shares in the last quarter. Jane Street Group LLC increased its position in shares of Pacira BioSciences by 1,780.2% in the first quarter. Jane Street Group LLC now owns 187,531 shares of the company’s stock worth $5,480,000 after purchasing an additional 177,557 shares during the period. Park Place Capital Corp acquired a new position in Pacira BioSciences in the second quarter valued at about $46,000. Finally, GAMMA Investing LLC lifted its position in Pacira BioSciences by 229.6% during the second quarter. GAMMA Investing LLC now owns 1,338 shares of the company’s stock worth $38,000 after purchasing an additional 932 shares during the period. 99.73% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently commented on PCRX shares. Raymond James cut shares of Pacira BioSciences from an “outperform” rating to a “market perform” rating in a research report on Monday, August 12th. Barclays lowered their price objective on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a research report on Tuesday, November 12th. Truist Financial downgraded Pacira BioSciences from a “buy” rating to a “sell” rating and reduced their target price for the company from $30.00 to $8.00 in a report on Tuesday, August 13th. Piper Sandler cut Pacira BioSciences from an “overweight” rating to a “neutral” rating and lowered their price target for the stock from $42.00 to $11.00 in a report on Monday, August 12th. Finally, Royal Bank of Canada raised their price objective on Pacira BioSciences from $15.00 to $16.00 and gave the company a “sector perform” rating in a research note on Thursday, November 7th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $23.50.

Pacira BioSciences Trading Down 0.8 %

PCRX opened at $16.64 on Thursday. The company’s 50 day moving average price is $16.37 and its two-hundred day moving average price is $20.03. The firm has a market capitalization of $768.27 million, a price-to-earnings ratio of -8.20 and a beta of 0.82. Pacira BioSciences, Inc. has a fifty-two week low of $11.16 and a fifty-two week high of $35.95. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.